Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
hsa-miR-192
Specific or universal ncRNAs
Specific ncRNAs
Class
MicroRNA
Biomarker
No
Biomarker application
Upstream regulatory factors
Not available
Downstream target
Bcl-2
Cancer name
Lung Adenocarcinoma
Cancer site
Lung
Treatment type
Chemotherapy
Drug
Cisplatin/Gemcitabine
Impact of wild-type ncRNA on chemotherapy resistance
Impact of knockdown of ncRNA on chemotherapy resistance
Up
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
MiR-192 inhibitor treated tumor exhibits sensitivity to cisplatin and gemcitabine therapy.
Tissue resource
human lung adenocarcinoma cell lines A549
human bronchial epithelial cell lines NHBE
Experiment
qRT-PCR,Western blot
Institute
the Cell Bank of Chinese Academy of Sciences
Country
China
Continent
Asia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.